Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogren’s syndrome

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the benefits and harms of DMARDs in the treatment of Sjögren’s syndrome.

This is a protocol.

Published:

10 May 2021

Authors:

Gualtierotti R, Rota M, Lopez-Olivo MA, Spadari F, La Vecchia C, Cugno M

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Gualtierotti R, Rota M, Lopez-Olivo MA, Spadari F, La Vecchia C, Cugno M. Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogren’s syndrome (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD014529. DOI: 10.1002/14651858.CD014529.